652 related articles for article (PubMed ID: 25629635)
1. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.
Wu C; Zhao C; Yang Y; He Y; Hou L; Li X; Gao G; Shi J; Ren S; Chu H; Zhou C; Zhang J; Schmid-Bindert G
J Thorac Oncol; 2015 May; 10(5):778-783. PubMed ID: 25629635
[TBL] [Abstract][Full Text] [Related]
2. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
3. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
[TBL] [Abstract][Full Text] [Related]
4. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
5. Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth.
Kobayashi Y; Mitsudomi T; Sakao Y; Yatabe Y
Ann Oncol; 2015 Jan; 26(1):156-161. PubMed ID: 25361983
[TBL] [Abstract][Full Text] [Related]
6. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
8. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.
Sholl LM; Aisner DL; Varella-Garcia M; Berry LD; Dias-Santagata D; Wistuba II; Chen H; Fujimoto J; Kugler K; Franklin WA; Iafrate AJ; Ladanyi M; Kris MG; Johnson BE; Bunn PA; Minna JD; Kwiatkowski DJ;
J Thorac Oncol; 2015 May; 10(5):768-777. PubMed ID: 25738220
[TBL] [Abstract][Full Text] [Related]
9. Going beyond EGFR.
Zimmermann S; Peters S
Ann Oncol; 2012 Sep; 23 Suppl 10():x197-203. PubMed ID: 22987962
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
Gow CH; Hsieh MS; Wu SG; Shih JY
Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.
Zhou JX; Yang H; Deng Q; Gu X; He P; Lin Y; Zhao M; Jiang J; Chen H; Lin Y; Yin W; Mo L; He J
Ann Oncol; 2013 May; 24(5):1319-25. PubMed ID: 23277484
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
13. Driver Mutation Analysis and PD-L1 Expression in Synchronous Double Primary Lung Cancer.
Jia X; Zhang L; Wu W; Zhang W; Wu C
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):246-253. PubMed ID: 27438512
[TBL] [Abstract][Full Text] [Related]
14. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
[TBL] [Abstract][Full Text] [Related]
15. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.
Guisier F; Salaün M; Lachkar S; Lamy A; Piton N; Obstoy B; Sabourin JC; Thiberville L
Respirology; 2016 May; 21(4):718-26. PubMed ID: 27099101
[TBL] [Abstract][Full Text] [Related]
18. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.
Ren S; Kuang P; Zheng L; Su C; Li J; Li B; Chen X; Wang Y; KimCurran V; Liu L; Hu Q; Zhang J; Tang L; Zhou C
Cell Biochem Biophys; 2012 Nov; 64(2):155-60. PubMed ID: 22707299
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
20. Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.
Schneider F; Derrick V; Davison JM; Strollo D; Incharoen P; Dacic S
Mod Pathol; 2016 Jul; 29(7):735-42. PubMed ID: 27080983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
